Newly Emerging Immunotherapy for Pancreatic Cancer Treatment

Official title

A Phase Ib/II Platform Trial of Newly Emerging Immunotherapy for Pancreatic Cancer Treatment

Overview

This is a Phase Ib/II platform clinical study to evaluate the initial efficacy and safety of different novel immunotherapies in patients with advanced pancreatic cancer.

Detailed description

The cohort A/B/C included patients with unresectable locally advanced or metastatic pancreatic cancer who had previously failed at least first line gemcitabine-based system therapy.The cohort D/E/F included patients with previously untreated systemic pancreatic cancer with unresectable locally advanced or metastatic pancreatic cancer.This study plans to first explore A/B/C cohort, and then start the D/E/F cohort after determining the safety.

Interventions

• Drug JS001
  240 mg by IV infusionevery 3 weeks (Q3W), given on cycle day 1.
• Drug JS004
  200 mg by IV infusion Q3W, given on cycle day 1.
• Drug JS007
  3mg/kg by IV infusion Q3W, given on cycle day 1.
• Drug JS015
  600mg by IV infusion Q3W, given on cycle day 1.
• Drug Irinotecan Liposome Injection
  60 or 70 mg/m\^2 by IV infusion every 2 weeks (Q2W), given on cycle day 1.
• Drug 5-Fluorouracil (5-FU)
  2400mg/m\^2, intravenously, over 46 h on day 1, Q2W.
• Drug Leucovorin (LV)
  400mg/m\^2, intravenously, over 30 min on day 1, Q2W.
• Drug Nab paclitaxel
  125 mg/m\^2 by IV infusion Q3W, given on cycle day 1 and 8.
• Drug Gemcitabine
  1000 mg/m\^2 by IV infusion Q3W, given on cycle day 1 and 8.

Primary outcome measures

• Incidence of dose-limiting toxicity (DLT) (phase IB) [Time frame: 21 days after the first dose was administered to each subject]
• Objective Response Rate (ORR) (phase II) [Time frame: Up to 1 year]

Secondary outcome measures (6)

• Objective Response Rate (ORR) (phase IB) [Time frame: Up to 1 year]
• Disease control rate (DCR) [Time frame: Up to 1 year]
• Duration of Response (DOR) [Time frame: Up to 1 year]
• Progression free survival (PFS) [Time frame: Up to 2 years]
• Overall Survival (OS) [Time frame: Up to 2 years]
• Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment [Time frame: 90 days after the last administration]

Eligibility criteria

Inclusion criteria

• Voluntary participation, written informed consent, complied well and cooperated with the follow-up visits;
• Age ≥ 18 years old, female or male individuals;
• Eastern Cooperative Oncology Group (ECOG) Performance status score of 0 or 1, the expected survival is more than 3 months;
• Patients with locally advanced unresectable or metastatic pancreatic cancer confirmed by histopathology or cytopathology (islet cell tumor is not eligible for inclusion) who meet the following requirements:

• For the A/B/C/ cohort: Had failed of at least first-line systemic therapy; disease recurrence or progression within 6 months of the last treatment of neoadjuvant or adjuvant chemotherapy was also allowed to be enrolled;
• For the D/E/F cohort: No prior systemic treatment; patients with recurrence or progression of disease more than 6 months after the last treatment of neoadjuvant or adjuvant chemotherapy were also allowed to be enrolled;
• Had at least one measurable lesion according to RECIST v1.1.
• Patients had adequate major organs function;
• Women of childbearing potential must undergo serum pregnancy test within 7 days prior to the first dose and the result must be negative. Female subjects of childbearing potential and male subjects whose partners are women of childbearing potential must agree to use highly effective contraceptive methods during the study period and within 180 days after the last dose of study drug.

Exclusion criteria

• Previously received drugs with the same target as the planned investigational therapy;
• radiotherapy (except for palliative reasons), endocrine therapy, chemotherapy, immunotherapy, or molecular targeted therapy within 4 weeks prior to initial administration, except for bisphosphonates (which can be used for bone metastasis);
• Uncontrolled central nervous system metastases (meaning symptoms or the use of glucocorticoids or mannitol to control symptoms);
• A history of clinically significant or uncontrolled heart disease, including congestive heart failure, angina pectoris, myocardial infarction, or ventricular arrhythmia, in the 6 months prior to initial dosing;
• Patients with Grade 1 and above adverse reactions caused by previous treatment, including Grade 1 peripheral neurotoxicity; hair loss is not included and the investigator should clearly record the reasons;
• Malignant tumors within 5 years prior to the first dose (except for cured skin basal cell carcinoma and cervical carcinoma in situ);
• Active autoimmune disease requiring systemic treatment within 2 years prior to first administration, except for vitiligo, type I diabetes, residual hypothyroidism due to autoimmune thyroiditis requiring hormone replacement therapy only;
• History of rapid allergic reaction, eczema or asthma that cannot be controlled by topical corticosteroids;
• Patients who have lung disease, such as drug-induced interstitial lung disease or pneumonia, obstructive pulmonary disease that severely affects lung function, and symptomatic bronchospasm;
• Serious infections requiring antibiotic treatment within 14 days prior to initial administration (>CTCAE grade 2), such as severe pneumonia, bacteremia, comorbidifications, etc., resulting in the need for hospitalization;
• Vaccination of live vaccine within 4 weeks before the first dose or during the study period;
• Known human immunodeficiency virus (HIV) infection, allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
• History of prior allergy to any component or excipient of the investigational drug to be received;
• Other conditions assessed by the investigator as unsuitable for participation in the trial.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Non-randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

China · 1 center

• Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Canc — Shanghai

Identifiers

NCT: NCT06370754 · 2401289-19-2403

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗